<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-105734</identifier>
<setSpec>0304-5013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Influence of regulatory measures in the advertising of hormone replacement therapy</dc:title>
<dc:description xml:lang="en">Objective. To determine the influence of regulatory measures on safety in the advertising of medicines for hormone replacement therapy (HRT) and the quality of the information contained in these advertisements. Methods. Advertisements for HRT were identified in three journals and their characteristics, information, advertising messages and the advertising pressure index (API) were analyzed. Results. A total of 174 advertisements were identified. The API was low: 5.65, 4.96, 3.03 and 0.58 for 2002 to 2005, showing a drastic reduction in advertising due to the regulatory measures of the Spanish Agency for Medications and Healthcare Products. Forty-one alterations in information content were detected. Only 10% of messages were supported by published studies. Conclusions. a) Drug safety information can have a decisive influence on drug advertising in medical journals; b) the quality of the information contained in drugs advertising is very low and is frequently misleading (AU)</dc:description>
<dc:creator>Iglesias, Ana I</dc:creator>
<dc:creator>Hidalgo, Agustín</dc:creator>
<dc:creator>Diez, Brezo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivos. Determinar la influencia de medidas reguladoras sobre seguridad en la publicidad de medicamentos para la terapia hormonal sustitutiva (THS) y la calidad de la información de los anuncios. Métodos. En 3 revistas se identificaron los anuncios de medicamentos para THS, sus características, información, mensajes publicitarios y el índice de presión publicitaria (IPP). Resultados. Se identificaron 174 anuncios. El IPP fue bajo: 5,65, 4,96, 3,03 y 0,58 para los años 2002 a 2005, lo que demuestra una drástica reducción de la publicidad por las medidas reguladoras de la AEMPS. Se detectaron 41 alteraciones del contenido informativo. Solo el 10% de los mensajes estaban respaldados por bibliografía. Conclusiones. a) Las notas de seguridad de medicamentos pueden influir decisivamente en la publicidad de medicamentos en revistas médicas; b) la calidad de la información contenida en la publicidad es muy baja y, habitualmente, engañosa (AU)</dc:description>
<dc:source>Prog. obstet. ginecol. (Ed. impr.);55(9): 429-434, nov. 2012.</dc:source>
<dc:identifier>ibc-105734</dc:identifier>
<dc:title xml:lang="es">Influencia de las medidas reguladoras en la publicidad de la terapia hormonal sustitutiva</dc:title>
<dc:subject>^d^s22066</dc:subject>
<dc:subject>^d33862^s22066</dc:subject>
<dc:subject>^d33862^s22045</dc:subject>
<dc:subject>^d332^s22074</dc:subject>
<dc:subject>^d^s22045</dc:subject>
<dc:subject>^d4408^s22049</dc:subject>
<dc:subject>^d4408^s22048</dc:subject>
<dc:subject>^d332^s37748</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d4</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d28596^s22045</dc:subject>
<dc:subject>^d28596^s22066</dc:subject>
<dc:subject>^d7432^s22049</dc:subject>
<dc:subject>^d28596^s22074</dc:subject>
<dc:subject>^d16712</dc:subject>
<dc:subject>^d24536</dc:subject>
<dc:subject>^d332^s22048</dc:subject>
<dc:type>article</dc:type>
<dc:date>201211</dc:date>
</metadata>
</record>
</ibecs-document>
